TW202308654A - 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 - Google Patents

19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 Download PDF

Info

Publication number
TW202308654A
TW202308654A TW111116469A TW111116469A TW202308654A TW 202308654 A TW202308654 A TW 202308654A TW 111116469 A TW111116469 A TW 111116469A TW 111116469 A TW111116469 A TW 111116469A TW 202308654 A TW202308654 A TW 202308654A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
anxiety
ham
Prior art date
Application number
TW111116469A
Other languages
English (en)
Chinese (zh)
Inventor
羅伯特 阿爾方索 雷舍
詹姆士 多赫提
杰佛瑞 馬丁 強納斯
史帝芬 傑 凱恩思
布魯斯 漢丹 剛杜斯
海倫 科昆皇
萊恩 阿諾德
維傑爾 邦沙帕利
喬伊 麗莎 鄧巴
班邦 慎諾雅吉 愛帝維加雅
Original Assignee
美商賽吉醫療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商賽吉醫療公司 filed Critical 美商賽吉醫療公司
Publication of TW202308654A publication Critical patent/TW202308654A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW111116469A 2021-04-29 2022-04-29 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法 TW202308654A (zh)

Applications Claiming Priority (16)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US63/181,743 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US63/197,025 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US63/210,810 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US63/239,096 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US63/285,812 2021-12-03
US202163289520P 2021-12-14 2021-12-14
US202163289506P 2021-12-14 2021-12-14
US63/289,520 2021-12-14
US63/289,506 2021-12-14
US202263298601P 2022-01-11 2022-01-11
US63/298,601 2022-01-11

Publications (1)

Publication Number Publication Date
TW202308654A true TW202308654A (zh) 2023-03-01

Family

ID=81748925

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111116469A TW202308654A (zh) 2021-04-29 2022-04-29 19-nor-c3,3-二取代c21-n-吡唑基類固醇及其使用方法

Country Status (11)

Country Link
US (1) US20240216395A1 (enExample)
EP (2) EP4768044A2 (enExample)
JP (2) JP2024515829A (enExample)
KR (1) KR20240006026A (enExample)
AU (1) AU2022266680A1 (enExample)
BR (1) BR112023022264A2 (enExample)
CA (1) CA3218072A1 (enExample)
IL (1) IL307991A (enExample)
MX (1) MX2023012727A (enExample)
TW (1) TW202308654A (enExample)
WO (1) WO2022232504A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ，インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof
JP2025508406A (ja) * 2022-02-16 2025-03-26 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ関連障害を処置するための神経活性ステロイド

Also Published As

Publication number Publication date
EP4329770A1 (en) 2024-03-06
CA3218072A1 (en) 2022-11-03
US20240216395A1 (en) 2024-07-04
WO2022232504A1 (en) 2022-11-03
JP2024515829A (ja) 2024-04-10
JP2025111701A (ja) 2025-07-30
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
EP4768044A2 (en) 2026-07-01
AU2022266680A1 (en) 2023-11-02
BR112023022264A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
US20240216395A1 (en) 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
US10278977B2 (en) Methods for treating hypersomnolence
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine